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Abstract 
Aneuploidy is a hallmark of most human tumors, but the molecular physiology of aneuploid 
cells is not well characterized. In this study, we screened cell surface biomarkers of ~300 
proteins by multiparameter flow cytometry using multiple aneuploid model systems such as 
cell lines, patient samples and mouse models. Several new biomarkers were identified with 
altered expression in aneuploid cells, including overexpression of the cellular prion protein 
CD230/PRPC and the immunosuppressive cell surface enzyme ecto-5'-nucleotidase CD73. 
Functional analyses associated these alterations with increased cellular stress. An increased 
number of CD73+ cells was observed in confluent cultures in aneuploid cells relative to their 
diploid counterparts. An elevated expression in CD230/PRPC was observed in serum-
deprived cells in association with increased generation of reactive oxygen species. Overall, 
our work identified biomarkers of aneuploid karyotypes which suggest insights into the 
underlying molecular physiology of aneuploid cells. 
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Introduction 
 
Aneuploidy refers to an abnormal chromosome number that differs from multiples of the 
haploid set. Due to its negative effect on cellular physiology, it is considered to be the 
leading cause of spontaneous miscarriages in humans and can cause pathological conditions 
such as trisomy syndromes (e.g. Down’s syndrome, trisomy of chromosome 21) and mosaic 
variegated aneuploidy (1). In addition, aneuploidy has also been tightly associated with 
cancer and, in contrast to cases with trisomy syndromes, malignant tumors often show 
variable aneuploid karyotypes with no apparent adverse effect on cell proliferation (2). In 
fact, it has been hypothesized that aneuploidy in vivo facilitates tumorigenesis and generates 
phenotypic variation, thus providing a growth advantage under selective conditions (3,4). 
Such phenotypic heterogeneity arises mainly from chromosomal instability (CIN), which is 
characterized by increased rate of loss/gain of whole chromosomes or parts thereof. In 
tumor cells, aneuploidy is often accompanied by CIN, which provides a mechanism to boost 
tumor progression due to emergence of cells with growth or survival advantages, the driving 
force of cancer development (5). This might be the reason why, in many types of cancer, 
higher levels of aneuploidy have been associated with poor prognostic factors such as higher 
tumor grade, tumor recurrence, metastasis and decreased overall patient survival (6). 
The identification of biomarkers related to aneuploidy, or even to specific characteristics of 
aneuploid cells that may allow them to survive under specific conditions such as cellular 
stress, would not only increase our insight into its biological background, but would also 
facilitate the development of an early screening tool to detect and/or quantify aneuploidy in 
tumors, ultimately improving the clinical management of cancer patients. In line with this, a 
major focus of current research is to determine how cells respond to gene expression 
imbalances that are caused by aneuploidy (7,8). In the past years, global genome, 
transcriptome and proteome studies in aneuploid models as well as in cancers have 
provided new insights into the cellular response to aneuploidy (7-13). Such studies indicate 
that copy number variations (CNV) of specific chromosomal regions can alter the expression 
of genes located on those regions. At the same time, aneuploidy per se can affect the 
transcription of many genes across the entire genome due to activation/inhibition of 
multiple pathways (11,12). Similarly, protein levels also scale with the gene copy number 
(CN), although it should be noted that some of the proteins coded on extra chromosomes 
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are compensated by post-translational mechanisms that attenuate their levels when their 
encoding genes are in excess (e.g. subunits of macromolecular protein complexes and 
kinases) (7,8). However, the exact cellular and physiological responses to aneuploidy are 
incompletely understood. In the past years, several new models have been established in 
order to decipher the consequences of aneuploidy. These include mouse models (14), 
human tri/tetrasomic cells generated by introducing one or more individual chromosomes 
into a host cell, and embryo- and patient-derived cell lines with trisomy syndromes (2).  
In this study, we aimed at identifying cell surface biomarkers correlated with an aneuploid 
karyotype by analyzing multiple models of aneuploidy for expression of approximately 300 
proteins by multi-parameter flow cytometry (MFC). This approach allows for the 
measurement of multiple features on a single cell level and thereby a direct analysis of cell 
surface marker expression, which makes it a powerful method not only for the 
immunophenotypic characterization of cells, but also for the identification of novel 
biomarkers. In the study presented here, several new biomarkers have been identified to be 
associated with an aneuploid karyotype. Functional analysis showed that the main 
candidates were associated with the response to specific stress conditions, such as oxidative 
stress. Taken together, our findings provide novel tools to detect and analyze cells with 
aneuploid chromosome settings, as well as additional functional insight into the subsequent 
cellular stress arising in response to aneuploidy. 
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Material and Methods 
 
Cell lines, patients’ fibroblasts and culture conditions 
The aneuploid cell lines used as a model in the present study were generated from the 
parental cell line HCT116 (human colorectal carcinoma cell line) - HCT116 13/3 (trisomy 13; 
clones 2-3), HCT116 18/3 (trisomy 18; clones 1-2) and HCT116 21/3 (trisomy 21; clones 1 and 
3) -, the parental cell line HCT116 H2B-GFP - HCT116 3/3 (trisomy 3; clones 11 and 13), 
HCT116 5/3 (trisomy 5), HCT116 8/3 (trisomy 8; clones 3, 5 and 7), HCT116 5/4 (tetrasomy 5) 
and HPT (post-tetraploid; clones 1, 2 and 4) -, the parental cell line RPE1 (human retinal 
pigment epithelial cell line, hTERT immortalized) - RPE1 3/3 (trisomy 3; clone 1), RPE1 5/3 
(trisomy 5; clone 3 and 7), RPE1 12/3 (trisomy 12) and RPE1 5/3 12/3 (trisomy 5, 12) -, the 
parental cell line RPE1 H2B-GFP - RPE1 3/3 (trisomy 3; clone 2), RPE1 21/3 (trisomy 21) and 
RPT (post-tetraploid; clones 1, 3 and 4) -, and the parental cell line DLD1 (human colon 
adenocarcinoma cell line) - post-tetraploids with karyotype near-3N (clones 7, 13, 16), 4N 
and >4N -. All tri- and tetrasomic cell lines were generated by microcell mediated 
chromosome transfer (MCMT) as described previously and verified by sequencing 
(7,11,15,16). The post-tetraploid HPT and RPT cell lines were generated by expansion of 
individual tetraploid clones after inhibition of cytokinesis through dihydrocytochalasin D 
(DCD, Sigma-Aldrich, St. Louis, MO, USA) treatment, and the DNA content was confirmed by 
flow cytometry, standard karyotyping, chromosome painting and array comparative genomic 
hybridization as previously described (11,17). Additional tetraploid clones were generated 
previously by FACS-sorting of spontaneously arising tetraploids within the HCT116 
population (18). Diploid and tetraploid DLD1 cell lines were described previously (19) and 
spontaneously arising post-tetraploids were selected from the tetraploid population by FACS 
sorting, as described in detail elsewhere (20 and Viganó et al., unpublished). All the cell lines 
were tested for mycoplasma contamination. Table 1 includes an overview of all cell lines 
included in the study, with the corresponding karyotype and clones, as well as reference of 
origin. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM high glucose, 
Gibco), supplemented with 10% fetal calf serum (FCS), 100U penicillin and 100U 
streptomycin (LONZA) and maintained at 37°C with 5% CO2 atmosphere. Fibroblasts from 
patients with trisomy syndromes were purchased from the Coriell Institute (Camden, New 
Jersey, USA), with +21 karyotype (No. GM01137A, GM02767D and AG06872A), +18 
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karyotype (No. AG12614 and GM03538) and +13 karyotype (No. AG10292), and maintained 
in culture according to suppliers' specifications (http://catalog.coriell.org). IMR-90 (#CCL-186, 
ATCC, Manassas, VA) normal human fibroblasts were used as control. Cells were detached 
using either Trypsin-EDTA (Sigma-Aldrich), or Accutase (Merck Millipore, Billerica, MA, USA) 
for the cell surface marker screenings, followed by centrifugation at 300 g for 5 min. 
 
Mouse models of aneuploidy  
Mouse tumors were obtained from TetO-Her2, TetO-KrasG12D/MMTV-rtTA with and 
without Mad2 overexpression (21) as well as a new transgenic animal model TetO-
PLK1/TetO-Her2/MMTV-rtTA (Venkateswaran et al. unpublished). Single cells obtained from 
these tumors were injected into the cleared mammary fat pad of Rag2-/- mice (22) 
maintained on a doxycycline diet to regrow the primary tumor. Surgical procedures were 
performed under isoflurane inhalation (2.5% in 0.8 L/min, Esteve) and in accordance with 
local disinfection and sterilization guidelines. R1 and R15 tumors used in the study had a Kras 
genotype, R16 and R10 a Kras/Mad2, R4 and R5 a PLK1/Her2, and the R3 had a Her2 
genotype. The tumors were genetically characterized as previously described (21): R10 
(whole-chromosome gain of chromosomes 1 and 8 and loss of chromosomes 4, 5, 9, 10, 14, 
16, 18 and x), R5 (gains of chromosomes 6 and 18, loss of chromosome 16 and a complex 
rearrangement on 10) and R4 (gains of chromosomes 1, 3 and 18) tumors were highly 
aneuploid, while R16 (loss of chromosome 4), R1 and R15 (no SCNA identified by WGS) were 
considered low aneuploid tumors.  
 
Cell surface marker screening of aneuploid cells 
Cells were analyzed using the MACS® Marker Screen, human (Miltenyi Biotec, Bergisch 
Gladbach, Germany) containing 300 antibodies (Ab) APC-conjugated - 291 antibodies specific 
for surface proteins plus 9 isotype controls (Supplementary Table S1), arrayed in four U-
bottom 96-well plates (one Ab/well). Before staining, lyophilized Abs were reconstituted 
with 25μL/well of deionized water. Cells were stained at a density of 0.5-2x105 cells per well 
in 50μL volume of PBS pH 7.2, 2 mM EDTA and 0,5% BSA (PEB) buffer at 2-8°C for 10 min, 
followed by 2 washing steps with PEB. To analyze four cell lines simultaneously per screening, 
cells were labeled using CellTrace™ Violet and/or CFSE (Life Technologies, Carlsbad, CA, USA) 
at concentrations of 0.5-3 μM before the Ab staining, according to the manufacturer’s 
Research. 
on December 12, 2018. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 4, 2017; DOI: 10.1158/0008-5472.CAN-16-3052 
 
 
8
instructions, and later gated in a V1(VioBlue)-A vs B1(FITC)-A plot. For those cell lines 
expressing H2B-GFP, only CellTrace™ Violet was used. Analysis was performed using the 
MACSQuant™ Analyzer and data analysis using the MACSQuatify™ software (Miltenyi Biotec). 
Propidium iodide (PI, 1μg/mL) was used as viability dye. For validation screenings, a specific 
panel was established (Supplementary Table S2) and cells were stained as previous with an 
antibody dilution of 1:10.  
It is known that some aneuploid cell lines are larger than their euploid counterparts. In the 
flow cytometer used in our study, cells are investigated inside of a well-defined three-
dimensional region. This region is defined in one dimension by the hydrodynamically focused 
core stream carrying all cells with a diameter typically smaller than 15 µm. Cells can be larger 
than 15 µm in their natural environment or in an adherent state, however, when dissociated 
and put into a single cell suspension, cells round up and are significantly smaller. In the two 
other dimensions it is defined by the intersection of the laser excited volume and 
perpendicular to it by the volume imaged onto the light detector tubes (PMT). The resulting 
“observed volume” is in the order of 15 µm x 15 µm x 15 µm and has a fuzzy boundary. All 
fluorescence inside of that volume are taken into account for quantitation. The remaining 
unbound molecules within that volume, are quantified as well as all fluorescent molecules 
bound to the cell. The background signal is then subtracted from the signal collected while a 
cell is present. Thus, if there is a significant background contribution (e.g. by unbound 
fluorochrome-conjugates), a larger cell will displace more of that than a smaller cell. But 
other than that, the total fluorescence is detected independent from the cell size, as long as 
the cell fits completely in said observed volume. As a consequence, the measured signal is 
proportional to the total number of molecules bound to the cell, independent from cell-size. 
To verify this theoretical prediction and to exclude a bias of the cell size on the fluorescence 
intensity of the cell surface marker staining, we have plotted FSC signals versus fluorescence 
signals and observed no correlation (data not shown). Concerning the issue of unbound dyes, 
unstained cells are the best control, since a larger unstained cell population will displace 
more unbound particles and as a consequence should have a lower (even negative) average 
mean fluorescence when compared to smaller cells. We included unstained controls for 
every cell line analyzed without observing this issue.  
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Cell surface marker screening of mouse tumors 
Tumor tissue was dissociated into a single cell suspension using the Tumor Dissociation Kit, 
mouse (Miltenyi Biotec), in combination with the gentleMACS Octo Dissociator with heaters 
(Miltenyi Biotec) according to the manufacturer’s instructions. CellTrace™ Violet (Life 
Technologies) staining was used as previously described in order to analyze simultaneously 
two tissue samples (tumor and/or normal mammary gland) per screening, followed by 
staining with a cocktail of monoclonal antibodies for non-tumor cell exclusion (CD45, clone 
30F11; Ter119, clone Ter-119; CD31, clone 390; CD90.2, clone 30-H12; conjugated to APC or 
FITC; dilution 1:10, all Miltenyi Biotec). Cells were then stained with a panel of 29 cell surface 
mouse antibodies plus 7 isotype controls PE-conjugated, arrayed in a U-bottom 96-well plate 
(Supplementary Table S3). 
 
siRNA-mediated knockdown  
For knockdown of expression of candidate genes, HCT116 (parental cells, control) and HPT1-
H2B GFP (selected as representative for aneuploidy) cells were transfected with small 
interfering RNAs (siRNAs) using MACSfectinTM Reagent (Miltenyi Biotec). A mixture of four 
small interfering RNAs (ON-TARGETplus SMARTpool siRNAs) for NT5E (CD73; 4905), PRNP 
(CD230; 5621), CD55 (1604), FAS (CD95; 355), CD47 (961) and ITGA2 (CD49b; 3673) were 
obtained from Dharmacon (Lafayette, CO, USA). ON-TARGETplus Non-targeting Pool was 
used as negative control. 0.5x105 cells were seeded per well in a 24 multi-well plate and, 
after 24h and 70% confluence, the siRNA molecules (final concentration 25 nM) were 
transfected with 1μL of MACSfectin per well according to manufacturer's instructions. Forty-
eight and 96h after seeding and transfecting the first time, cells were re-plated and re-
transfected with the same conditions. The knockdown efficiency was examined by flow 
cytometry 144h after transfection with the siRNA, and cell proliferation/cell death analyzed 
as described below. 
 
Flow cytometry-based analyses 
To determine whether depletion of candidates had an effect on specific cellular functions, 
different analyses were performed. For cell cycle analysis, cells were fixed with 4% 
paraformaldehyde (PFA) 20min and stained with 1µg/mL DAPI in a 0.5% saponin solution for 
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30min. For apoptosis detection, cells were stained with Annexin V-PE (Miltenyi Biotec) and 
DAPI, according to manufacturer's instructions. Apoptotic cells are positive for Annexin V 
whereas DAPI+ cells have recently died. For cell proliferation, incorporation of EdU (5-
ethynyl-2´-deoxyuridine) during DNA synthesis was measured using Click‑iT® EdU Flow 
Cytometry Assay Kit (Life Technologies), following manufacturer's instructions. Briefly, cells 
were incubated with 10µM EdU for 2h, collected and washed with 1% BSA in PBS, fixed with 
4% PFA 15min, permeabilized with saponin-based buffer 15min, stained with the Click‑iT 
reaction cocktail (containing CuSO4 and Alexa Fluor® 647 azide) for 30min and stained with 
1µg/mL DAPI. Analysis was performed using the MACSQuant™ Analyzer and data analysis by 
MACSQuatify™ software (Miltenyi Biotec). 
 
Induction and detection of specific stress conditions 
To determine how specific stress conditions might affect cell growth, as well as the level of 
expression of candidate markers, aneuploid cells were exposed to serum-starvation, glucose-
deprivation, high confluency, oxidative stress (H2O2), or ER stress (Brefeldin, BFA; 
Thapsigargin, Thps; or Tunicamycin, TM). For this set of experiments, HCT116 18/3 (clones 1 
and 2), HCT116 21/3 (clones 1 and 3) and HPT1 cell lines were used, together with HCT116 
parental cell line as control.  
To determine the effect of growth under high confluence, each cell line was plated in a 6-
well plate at a density of 2x105 cells per well and re-plated every 3 days (control) or 6 days 
(confluent) for 18 days. For the remaining stress conditions, cells were plated in a 6-well 
plate at a density of 2x105 cells per well and, after 24h, the medium was replaced by 
standard culture medium without FBS (serum-free) or without glucose (glucose-free), or 
treated with 100 µM H2O2, 1 μg/mL BFA, 0.25 μg/mL Thps or 2.5 μg/mL TM (all purchased 
from Sigma-Aldrich), for 2-3 days. After treatment, cells were collected and stained with Abs 
for the specific markers selected, at a dilution 1:10 at 2-8°C for 10 min, followed by 2 
washing steps with PEB.  
For oxidative stress detection, the CellROX® Deep Red Reagent (Life Technologies) was used 
to evaluate the levels of reactive oxygen species (ROS) by flow cytometry. For this purpose, 
the medium was removed from each well and cells were re-incubated with CellROX® 
Reagent at a final concentration of 5 μM, 30min at 37°C, before analysis. For ER detection, 
cells were stained 30min with anti-PDI PE antibody (clone 1D3, 1:100, Abcam, Cambridge, 
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UK), after fixation with 4% PFA 15min RT and permeabilization with saponin-based buffer 
15min RT. 
 
Statistical analysis 
All statistics and final plots were obtained using GraphPad Prism 6 software and all 
statistically evaluated experiments were performed in three replicates from at least two 
independent experiments.  
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Results 
 
Identification of differentially expressed cell surface markers in aneuploid cells 
Two adherent parental cell lines, RPE1 and HCT116, were used to generate cells with an 
aneuploid karyotype by transferring an additional chromosome via microcell-mediated 
chromosome transfer (to induce trisomy of chromosome 5, 12, 21 or others), or by inhibiting 
cytokinesis to generate more complex karyotypes (post-tetraploidy) (7,17) (for more details 
see Material and Methods). To identify cell surface molecules differentially expressed as 
compared to the parental cell lines, all cells were analyzed by flow cytometry using a cell 
surface marker screening panel containing antibodies specific for 291 surface proteins. Two 
sets of aneuploid cell lines, including three cell lines generated from the RPE1 parental line 
(RPE1 5/3 12/3, RPE1 21/3 and RPT1) and two from HCT116 parental line (HCT116 5/3 and 
HCT1), were initially screened with the complete panel of antibodies. Figure 1A-C shows the 
gating strategy used for the simultaneous analysis of 4 cell lines – 3 aneuploid plus one 
parental cell line - as well as the read-out of the analysis showing the expression levels for 
each marker (Figure 1D-I). To detect cell surface markers related to aneuploidy, the 
trisomic/post-tetraploid cell lines were compared to the corresponding parental cell line and 
all the markers that were differentially regulated were selected for further validation 
(Supplementary Figure S1). We measured the mean fluorescence intensity and percentage 
of positive cells for each surface marker staining across different cell lines (Supplementary 
Table S4). Analysis of the expression pattern showed 72/291 proteins with altered levels of 
expression in at least two of the aneuploid karyotypes when compared to the control 
(HCT116 and RPE1 parental cells); 20 and 18 of the 72 markers were altered in terms of 
mean intensity value and/or percentage of positive cells in five and four of the screened 
aneuploid cell lines, respectively. Based on these results, a new 49-marker panel (with 
additional 5 isotype control antibodies) with the most important candidates was developed 
for further analyses (Supplementary Table S2). 
 
Validation of candidate markers in independent cell lines 
In order to validate the most relevant candidates identified in the two initial high-throughput 
screenings, 25 additional aneuploid cell lines with different karyotypes were analyzed (e.g. 
trisomy of chromosome 3, 8, 13 and 18) with the 49-marker panel. In addition, 5 post-
Research. 
on December 12, 2018. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 4, 2017; DOI: 10.1158/0008-5472.CAN-16-3052 
 
 
13
tetraploid cell lines generated from the DLD1 parental cell line were also included (Table 1). 
For the majority of the clones analyzed in this study, at least two repetitive screenings were 
performed, with a total of 74 analyses for a total 35 aneuploid cell lines. Surface marker 
analysis revealed CD230 (PrP, prion protein) as the most frequently increased marker in 
aneuploid cells compared with the corresponding parental cells (66/74 analysis and 27/35 
aneuploid clones). In addition, aneuploid cells showed upregulation of several other markers, 
including the CD58 cell adhesion molecule (56/74 analyses and 24/35 aneuploid clones), the 
CUB domain-containing protein CD318 (55/74 analyses and 26/35 aneuploid clones), the 
Na+/K+-ATPase subunit CD298 (52/74 analyses and 23/35 aneuploid clones), the HLA-Bw6 
molecule (50/74 analyses and 23/35 aneuploid clones), the CD73/ecto-5'-nucleotidase 
(50/74 analyses and 22/35 aneuploid clones), the CD156c/ADAM10 protein (49/74 analyses 
and 21/35 aneuploid clones), the complement regulatory proteins CD46 and CD55 (49/74 
and 48/74 analyses and 21/35 and 22/35 aneuploid clones, respectively), the CD99 cell 
adhesion molecule (48/74 analyses and 24/35 aneuploid clones), and CD147/basigin (48/74 
analyses and 23/35 aneuploid clones), as well as several members of the integrin family of 
proteins - CD29 (61/74 analyses and 26/35 aneuploid clones), CD49b (56/74 analyses and 
29/35 aneuploid clones), CD47 (52/74 analyses and 26/35 aneuploid clones), CD49f (51/74 
analyses and 25/35 aneuploid clones) and CD104 (51/74 analyses and 24/35 aneuploid 
clones) - (Figure 2A). Of note, CD54/ICAM1 was the most frequently downregulated marker, 
with lower expression levels detected in 43/74 analyses and 21/35 aneuploid clones. Mean 
fluorescence intensity data and percentage of positive cells, normalized to the 
correspondent parental cell line, for all the clones and screenings are available in 
Supplementary Table S5. 
We next asked whether the changes in surface proteome correlate with the identity of the 
extra chromosome. Unsupervised hierarchical clustering revealed that most clones with the 
same extra chromosome cluster together, although there is certain heterogeneity, most 
likely due to clonal effects as each cell line arose from a single cell (Supplementary Figure S2). 
Importantly, comparison of different cell lines with the clones with the same trisomy showed 
that only a very few proteins were directly associated with the corresponding aneuploid 
chromosome. For example, the four clones with trisomy of chromosome 3 (i.e. RPE1 3/3 cl1 
and cl2 and HCT116 3/3 cl11 and cl13) all showed overexpression of CD318, with 
corresponding gene located on 3p21.31, and the clones with trisomy/tetrasomy of the 
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chromosome 5 (i.e. RPE1 5/3 cl3 and cl7 and HCT116 5/3 and 5/4) showed increased 
expression of the integrins CD49a and CD49b, coded on chromosome 5. However, CD318 
and both integrins were also upregulated in aneuploid cells that contain independent 
chromosomal amplifications. This indicates that there is only a minor role for chromosomal 
location and that the upregulated markers represent rather a response to aneuploidy per se. 
Taken together, we have identified 15 markers which are expressed at higher levels in 
human aneuploid cells than in the corresponding diploids in at least 60% of all analyzed lines. 
The elevated expression was independent of the cell line, the identity of the extra 
chromosome or the origin of aneuploidy. 
As marker detection by multiparameter flow cytometry was performed at the cell surface 
level, we used previously published proteome data (7) to confirm whether the expression 
difference reflects an increased expression or rather an altered localization at the cellular 
membrane. The available data characterized the proteome from trisomies of chromosome 3 
(HCT116 3/3), chromosome 5 (HCT116 H2B-GFP 5/3 and RPE-1 5/3) or chromosome 21 (RPE-
1 21/3), and tetrasomy of chromosome 5 (HCT116 5/4 and HCT116 H2B-GFP 5/4). The 
previously measured aneuploid-to-diploid ratios of protein abundance were compared with 
the relative changes of the surface proteins determined by flow cytometry (Supplementary 
Table S6). These data confirmed an increased abundance of most of the candidates, 
including increased expression of CD230 (PRNP), CD73 (NT5E), CD318 (CDCP1), CD298 
(ATP1B3), as well as the CD49b, CD29 and CD51 integrins, in at least five of the six aneuploid 
cell lines compared to their diploid counterparts.  
 
The overexpression of identified biomarkers is reproduced in primary fibroblasts from 
patients with trisomy syndromes and mouse models of aneuploidy 
To determine whether the differential expression of the identified candidate markers was 
also associated with aneuploidy in primary cases of trisomy syndromes, fibroblasts from 
patients with Down's (trisomy 21), Edwards' (trisomy 18) and Patau's (trisomy 13) 
syndromes were analyzed for the 49 surface markers. When compared with normal 
fibroblasts, patient samples showed overexpression of several markers, such as CD55 (12/12 
screenings), CD58 (12/12), CD99 (12/12), CD230 (11/12), CD90 (11/12), CD95 (10/12), CD97 
(10/12), CD147 (10/12), CD10 (10/12), CD73 (9/12) and PTk7 (9/12), in at least 5 of the 6 
patients (Figure 2B). Of note, similarly as in model aneuploidy cell lines, CD54 was one of the 
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most frequent markers (8/12 screenings) showing decreased expression in patients’ 
fibroblasts when compared to the normal counterparts.  
In more detail, comparisons among aneuploid cell lines and patients’ fibroblasts showed an 
increased expression of CD97, CD276, CD298, CD29, CD147, CD49e, CD49b and HLA-Bw6, as 
well as decreased expression of CD54 in cell lines with a trisomy of chromosome 13. Cells 
with trisomy 18 showed a common increased expression of CD55, CD58, CD99 and CD138, in 
addition to a decreased expression of CD142. On the other hand, trisomy of chromosome 21 
showed higher CD119, CD147 and HLA-Bw6 and lower CD54 expression, on both aneuploid 
cells and patients’ fibroblasts. 
To further validate the candidate markers in a completely independent model system, we 
additionally analyzed an in vivo mouse breast cancer model of chromosomal instability. We 
used a previously generated mouse mammary tumor virus (MMTV)-driven, doxycycline-
inducible model (21,23), which overexpress KrasG12D or both Mad2 and KrasG12D, since the 
later tumors have been shown to be highly aneuploid (21). To complement our study, we 
also used mouse tumors overexpressing Her2 or both Her2/PLK1 genes (Venkateswaran et 
al., unpublished). The mammary adenocarcinomas were characterized according to the CN 
profile, divided into low- (R1 and R15), intermediate- (R16 and R3) and high-aneuploidy 
(R10) tumors, and were compared to normal mammary gland tissue. Interestingly, several of 
the proteins showed comparable patterns of expression in the mouse cells as those 
observed in their human counterparts. Of note, the results showed an overexpression of the 
ecto-5'-nucleotidase (CD73) in all the mouse adenocarcinomas when compared to normal 
mammary cells, with higher levels of expression and percentage of positive cells (Figure 3), 
as well as increased expression of the mouse H-2Kd/2Dd MHC Class I antigens, the CD146 and 
CD44 cell adhesion molecules and the CD97v2 receptor (Supplementary Table S7). In 
addition, higher levels of expression were also detected in the high-aneuploidy tumors when 
compared to the low-aneuploidy ones, for several members of the integrin (i.e. CD29, CD47, 
CD49f and CD104) and tetraspanin (i.e. CD9, CD63 and CD151) family of proteins 
(Supplementary Table S7). Taken together, these results strongly indicate that the identified 
markers are generic and broadly applicable across aneuploid cells in the human and murine 
settings. 
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Expression of CD230 and CD73 in aneuploid cells changes in response to cellular stress  
To characterize possible roles of the identified markers on aneuploidy, 6 candidates - the 
major prion protein (CD230), the ecto-5'-nucleotidase (CD73), the CD55 complement 
regulatory protein, the CD95 Fas receptor and two members of the integrin family of 
proteins (CD49b and CD47) - were selected for further functional analyses. Depletion of the 
candidates by siRNA-mediated knockdown showed no major effect on cell proliferation (% 
EdU+ cells) and cell death (%AnnexinV+ cells), when compared to the non-targeting siRNA 
control on both the HCT116 parental and HPT1 cells (Supplementary Figure S3). Therefore, 
the expression of those markers seems to be non-essential for the cells, at least over limited 
period of time and under the tested conditions.  
We next investigated whether the expression of selected candidates correlates to specific 
stress conditions known to affect aneuploid cells. Aneuploidy is known to induce cellular 
stress (24) and recent reports suggest an association between aneuploidy and an 
advantageous phenotype under stress conditions (3). Aneuploid clones with negative or low 
expression of the markers (HCT116 18/3 cl2 and 21/3 cl1 and 3) were compared to clones 
with high levels of expression (HPT1 and HCT116 18/3 cl1), as well as HCT116 parental cells 
as control. The investigated stress conditions included growth at a high confluency, serum-
starvation, glucose-deprivation, oxidative stress and ER stress. To evaluate whether the 
stress conditions could alter the expression of those candidates, cells were initially grown 
under high confluency. Results showed a significant increase in the percentage of CD73+ cells 
for both HCT116 21/3 clones (p<0.0001, 0 vs 6, 6 vs 12 and 12 vs 18 days) compared to 
parental cells (p<0.0001, 0 vs 6 days) (Figure 4A). Of note, parental cells showed only a slight 
initial increase in the percentage of CD73+ cells, which stabilized over the time period of the 
experiment (Figure 4A and B). This indicates that the stress response and corresponding 
CD73 expression is significantly increased in aneuploid setting.  
We next analyzed whether cells with different degrees of aneuploidy show correlating levels 
of ER or oxidative stress. Whereas no significant differences were found for clones with only 
one extra chromosome, near-tetraploid clones, associated with higher levels of aneuploidy, 
showed higher expression of the ER stress marker protein disulfide isomerase (PDI), as well 
as higher reactive oxygen species (ROS), when compared to parental cells (p<0.01; Figure 5A 
and B). To further evaluate the impact of ER stress on aneuploid cells, we determined the 
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effect of glucose-deprivation, 1ug/mL brefeldin A, 0.25ug/ml thapsigargin or 2.5ug/mL 
tunicamycin on the expression levels of the candidates. However, results suggested a 
general decrease for mean fluorescence intensity of the cell surface markers, as the 
treatment probably blocked the assembly of new proteins in the ER and/or the transport of 
proteins from the ER to the cell surface (Supplementary Figure S4). To test the effect of 
oxidative stress, we treated cells with 100µM H2O2, a commonly used method to induce 
oxidative stress in cells (25). We observed a general increase for all analyzed proteins, most 
particularly for the CD95 FAS receptor, possibly due to the high toxicity of the treatment 
(Supplementary Figure S5).  
In addition, we tested the response of cells to 3 days of FBS-starvation as an alternative 
approach to induce oxidative stress with lower toxic effects (26). Indeed, the results revealed 
that serum-starvation (0% FBS), but not glucose-deprivation increased the generation of ROS 
in both parental and aneuploid cells (p<0.01 vs cells growing under 10% FBS; Figure 5C). The 
increased ROS resulted in an increase in the mean fluorescence intensity and/or percentage 
of positive cells of CD73, CD49b, CD95, and CD230, with CD230 showing the most significant 
increase (Figure 5D). Furthermore, all clones showing an intermediate expression of CD230 
became CD230 positive (HCT116 18/3 cl2, HCT116 21/3 cl1 and 3, as well as HCT116 wild-
type), while those clones already expressing CD230 (HPT1 and HCT116 18/3 cl2) showed a 
significant increase in the mean intensity level (p<0.001 vs 10% FBS control cells; Figure 5D 
and Supplementary Figure S6). These results suggest that serum-starvation increases the 
expression of CD230 in response to increased oxidative stress. Subsequent depletion of 
CD230 by siRNA-mediated knockdown followed by 3 days of FBS-starvation showed no 
significant effect on cell proliferation (data not shown), but a significant increase in the 
percentage of necrotic DAPI+ HPT1 aneuploid cells compared to the non-targeting siRNA 
control (p<0.001; Figure 5E). A slight, but not significant increase of necrosis as well as 
elevated percentage of apoptotic (Annexin V+) cells was also detected in HCT116 parental 
cells. These results confirm an important role of CD230 in cell survival upon oxidative stress, 
which is further emphasized in cells already compromised by aneuploidy. 
Taken together, our data indicate that overexpression of the identified cell surface markers, 
particularly CD230 and CD73, is correlated to cellular stress, which is increased in cells with 
aneuploid chromosome settings and might confer survival advantages under stress 
conditions.  
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Discussion  
 
The possible impact of aneuploidy on human health has been recognized for over a century, 
but its effects at the cellular level, such as the specific phenotype arising from aneuploidy, 
have only become a focus in more recent studies (2). Moreover, transcriptome and 
proteome analysis revealed common expression changes, suggesting the possibility that 
some of these changes might be used as markers of aneuploidy. In the present study, we 
applied a novel cell surface marker screening analysis to evaluate the expression pattern of 
291 proteins in order to identify biomarkers related to aneuploidy. Using this strategy we 
aimed not only to determine surface marker candidates, which would allow to detect and/or 
quantify aneuploidy in tumors, but also to provide insights into the underlying mechanisms 
that allow the cells with aneuploid karyotypes to grow despite the detrimental effects of 
aneuploidy on cellular physiology. To ensure a broad coverage of aneuploidy types, cells 
with one or two extra chromosomes (7), near-tetraploid karyotypes (17), embryo- and 
patient-derived cell lines with trisomy syndromes, as well as mouse models of aneuploidy 
(14) were all included in this study and screened for their surface proteome.  
Using this approach, we identified several proteins upregulated in aneuploid cells when 
compared to the corresponding diploid parental cells. Remarkably, the strongest candidates 
included proteins which have been previously associated with cancer, namely the prion 
protein (PrPC, CD230) (27), the ecto-5'-nucleotidase (ecto-5'-NT, CD73) (28), the CUB 
domain-containing protein CD318 (29), the Na+/K+-ATPase subunit CD298 (30), the 
disintegrin-metalloproteinase ADAM10 (CD156c) (31), the complement regulatory proteins 
CD46 and CD55 (32), the CD58 and CD99 cell adhesion molecules, the basigin (CD147) (33), 
as well as several members of the integrin family of proteins, e.g. CD29, CD49b, CD47, CD49f 
and CD104, which are expressed by tumor and tumor-associated host cells to mediate a 
diverse array of cellular effects resulting in tumor progression and metastasis (34). 
Interestingly, expression of several of these markers, such as CD230, CD73, CD55, CD58, 
CD99, was also elevated in primary fibroblasts from patients with Down's (trisomy 21), 
Edwards' (trisomy 18) and Patau's (trisomy 13) syndromes when compared to normal 
fibroblasts, thus suggesting a possible role for these proteins in aneuploid settings 
independent of cancer. 
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Using mouse models of aneuploidy, we further found that aneuploid mouse breast tumor 
cells also overexpress several of the identified candidate proteins such as the CD73 enzyme 
and multiple members of the integrin family of proteins. Interestingly, while the ecto-5'-NT 
enzyme was absent on both normal mammary gland cells as well as in non-tumoral lineages, 
all aneuploid tumors derived from four different mouse models (KrasG12D, KrasG12D/Mad2, 
Her2, and Her2/PLK1) harbored a subpopulation of tumor cells defined by the expression of 
this marker that ranged from 30% to 100 % of the tumor. Moreover, the expression levels 
often scaled with the degree of aneuploidy: the most aneuploid tumor (R10) showed the 
highest levels of CD73 expression while tumors with lower CNV showed only intermediate 
expression of CD73 in comparison to diploid cells. Of note, it is important to consider that 
not all the antibodies had a mouse specific counterpart (29 mouse/49 human specific Abs), 
thereby the expression intensity of some of the markers could not be validated in the 
respective mouse models. 
When taking all used models into account, two markers - PrPC and ecto-5'-NT - particularly 
stand out due to their low or absent expression in diploid cells, while the majority of the 
aneuploid cells showed a positive subpopulation, with variable percentages among the 
different clones and models (Figure 1F and I). PrP is well known for its role in the 
pathogenesis and transmission of prion diseases. Despite the abundant information on the 
function of the misfolded prion protein (PrPSc), the function of the cellular prion protein 
(PrPC) remains largely unknown (27). However, multiple reports have suggested a putative 
role for PrPC in cell signaling, survival, and differentiation (27,35,36) and, more recently, a 
large body of evidence suggests that PrPC is overexpressed in different types of cancers and 
its expression appears to be associated with poor prognosis and resistance to therapy (37-
41). Similarly, the ecto-5'-NT/CD73, a membrane-bound enzyme that catalyzes the hydrolysis 
of AMP into adenosine and phosphate, has also been found to be overexpressed in many 
types of cancer (28), with multiple key roles in tumor development. CD73 can act as a signal 
and adhesive molecule that regulates cell interaction with extracellular matrix components 
(e.g. laminin and fibronectin) to mediate cancer invasiveness and metastatic properties, as 
well as playing a key important role in the tumor immunoescape due to CD73-generated 
adenosine (42). In line with such evidences, our results suggest that increased surface 
abundance of these proteins may contribute to the phenotypic changes observed in 
aneuploid cells.  
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It is currently known that the aneuploid state of the cell elicits several cellular stress 
responses such as proteotoxic (24,43) and oxidative stresses (44). How these “aneuploidy-
associated stresses” affect cells and how cells respond to them are not yet clear (24,43). The 
possibility that aneuploidy triggers such stress responses in order to adapt and proliferate 
with their altered genomes has been recently proposed (24). In fact, evidences show that 
the effects of aneuploidy may become advantageous under environmental stress, most 
possibly due to the karyotypic/phenotypic heterogeneity arising in aneuploid cell 
populations caused by chromosomal instability, which ultimately provides superior 
adaptability and a growth advantage under selective conditions (24,45). Based on this, and 
due to the lack of an effect of marker-depletion on cell proliferation and cell death 
(apoptosis), we hypothesize that the expression of the marker candidates may be related to 
cellular stress. Indeed, our results showed that high levels of aneuploidy (i.e. the near-
tetraploid clones) were correlated with higher levels of both ER and oxidative stress. Most 
strikingly, clones with an extra copy of chromosome 21, which were initially negative for 
CD73, strongly increased the expression of CD73+ cells when grown under high confluency, 
while parental diploid cells only slightly increased expression early on and stabilized over 
time. A high confluency environment most certainly leads to hypoxia, a condition known to 
promote selection of resistant, aggressive cancer cells able to survive in unfavorable 
environments, with greater proliferative and migratory capacity (46). Accordingly, CD73 
expression can be driven by an hypoxic microenvironment as the CD73 gene promoter has at 
least one binding site for the hypoxia-inducible factor-1α (42,47) in order to convert AMP to 
adenosine and, consequently, to enhance tumor survival (46). Thus, we hypothesize that 
aneuploid cells might overexpress the ecto-5'-NT enzyme as a mechanism to gain protection 
under specific conditions and to support proliferation. In addition, under serum-free 
conditions both parental and aneuploid cells highly increased the expression of PrPC, as well 
as the generation of ROS, indicating that the higher levels of PrPC expressed by aneuploid 
cells (compared to normal cells) can probably confer an advantage against oxidative stress. 
Indeed, we found that aneuploid cells showed increased cell death under serum starvation 
after depletion of PrPC. These results are consistent with one of the emerging functions 
reported for PrPC, its protective role for cell survival, including protection against oxidative 
stress and serum deprivation (36), as well as hypoxia (48). In addition, PrPC has been 
described as an important modulator of tumor growth via engagement to the ligand 
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HSP70/90 heat shock organizing protein (49). Interestingly, Bravard et al. (50) also reported 
recently a key role of PrPC in the DNA damage response, suggesting that PrPC is required to 
maintain genomic stability in response to genotoxic stress. The authors showed that 
exposure to genotoxic stress activates PRNP transcription and increases the amount of PrPC 
in the nucleus, where it stimulates the endonuclease APE1, essential for base excision repair. 
Such evidences, together with our data, suggest that aneuploid clones might overexpress 
PrPC in order to increase protection from oxidative stress as well as DNA damage and, 
consequently, increase survival of aneuploid clones. Based on these data we propose that 
the identified changes in surface proteins reflect the cellular response to aneuploidy that is 
independent of the chromosome composition or the cell type. These proteins likely facilitate 
growth of aneuploid cells by protecting them from endogenous stresses caused by 
unbalanced karyotype. 
In summary, we have identified multiple cell surface biomarkers with altered expression in 
aneuploid cells. The most striking and general overexpression was seen for the CD230/PrPC 
protein and the enzyme CD73/ecto-5'-NT. Furthermore, we have shown that overexpression 
of both markers in aneuploid cells is associated to increased cellular stress, which may help 
to explain how aneuploidy confers a selective advantage to cells. CD230 and CD73 may 
therefore represent key markers to detect aneuploidy in healthy as well as tumor samples. 
Further studies to understand the full impact of these markers on aneuploid cells will not 
only deepen our knowledge on the consequences of an abnormal karyotype, but will also 
increase our insight into disabilities such as Down’s syndrome and diseases such as cancer. 
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Table 1. Overview of cell lines included in the study, with corresponding karyotype and 
clones. 
Karyotype nomenclature: 3/3, 5/3, 8/3, 12/3, 13/3, 18/3 and 21/3, trisomy of chromosome 3, 5, 8, 12, 
13, 18 and 21, respectively; 5/4, tetrasomy of chromosome 5; HPT, post-tetraploid generated from 
HCT116; TC, Tetraploid clone; RPT, post-tetraploid generated from RPE1. All the aneuploid cell lines 
generated from HCT116 and RPE1 were, unless otherwise indicated (a), developed at the Max Planck 
Institute of Biochemistry (Martinsried, Germany), and the DLD1-derived lines developed at the 
Biozentrum - University of Basel (Basel, Switzerland); (a) cell lines generated at the Francis Crick 
Institute (London, United Kingdom). (b) Number of cell lines used in the study are specified, instead of 
the ID of the clone. Fibroblasts from patients with trisomy syndromes were purchased from the 
Coriell Institute (Camden, New Jersey, USA). (ns) Clone number not specified.   
Parental cell line Karyotype Clones H2B-GFP Origin
HCT116 
3/3 11, 13 + Passerini et al. 2016 (16);  
Stingele et al. 2012 (7)  
5/3 ns + Passerini et al. 2016 (16);  
Stingele et al. 2012 (7) 
5/4 ns + Passerini et al. 2016 (16);  
Stingele et al. 2012 (7) ;  
Dürrbaum et al. 2014 (11) 
8/3 3, 5, 7 + Donnelly et al., 2014 (20) 
13/3 2, 3 - This study 
18/3 1, 2 - This study 
21/3 1, 3 - This study
5/3 3/3 ns - This study 
Near-4N (HPT) 1, 2, 4 + Kuznetsova et al. 2015 (17); 
Dürrbaum et al. 2014 (11) 
Near-4N (TC) a 4, 13, 17 - Dewhurst et al. 2014 (18) 
RPE-1 hTERT 
3/3 1, 2 -, + Stingele et al. 2012 (7) 
5/3 3, 7 - This study
12/3 ns - This study 
21/3 ns + Passerini et al. 2016 (16);  
Stingele et al. 2012 (7) ;  
Dürrbaum et al. 2014 (11) 
5/3 12/3 ns - Passerini et al. 2016 (16);  
Stingele et al. 2012 (7) ;  
Dürrbaum et al. 2014 (11) 
Near-4N (RPT) 1, 3, 4 + Kuznetsova et al. 2015 (17) 
DLD1 
Near-3N 7, 13, 16 - Viganó  et al. in preparation 
4N ns - Drosopoulos  et al. 2014 (19) 
>4N ns - Viganó et al. in preparation 
Patients with 
trisomy 
syndromes 
Patau‘s (13/3) 1 b - Coriell Institute No. AG10292 
Edwards‘ (18/3) 2 b - Coriell Institute No. AG12614 
and GM03538 
Down‘s (21/3) 3 b - Coriell Institute No. GM01137A, 
GM02767D and AG06872A 
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Figure legends 
 
Figure 1. Representative gating strategy and read-out for analysis of cell surface marker 
expression.  
Cells are first gated in a FSC-A vs SSC-A plot to exclude debris (A), followed by doublet 
exclusion on a FSC-A vs FSC-H plot (not shown) and dead cell exclusion on a PE-A vs PI-A plot 
(B). The cell lines included in the screening were then individually gated on a plot FITC-A 
(H2B-GFP+ or CFSE+ cells) vs VioBlue-A (VioDye+ cells) (C) for independent analysis of both 
percentage of positive cells and median fluoresce intensity levels (D-I); representative 
expression patterns of relevant candidates are shown. In the represented screening, four 
individual cell lines were included with H2B-GFP-/VioDye- (HCT116 parental cell line, black 
gate), H2B-GFP+/VioDye- (HPT2 post-tetraploid clone, green gate), H2B-GFP-/VioDye+ 
(HCT116 5/3 3/3 trisomies, blue gate) and H2B-GFP+/VioDye+ (HPT4 post-tetraploid clone, 
red gate) phenotypes. 
 
Figure 2. Identification of differentially expressed cell surface markers in aneuploid cells.  
Frequency of (A) aneuploid cell lines (n=74, 35 different aneuploid clones plus replicates) 
and (B) primary fibroblasts from patients with trisomy syndromes (n=12, 6 different patients 
plus replicates) showing increased or decreased expression of the 49 cell surface markers 
analyzed, compared to the corresponding parental cell line or diploid fibroblasts, 
respectively. Red and green bars indicate number of cases with increased and decreased 
expression, respectively, and each bar represents a different protein. At the bottom, 
representative Venn diagrams of three aneuploid cell lines (HCT116 5/4, HCT116 8/3 clone3, 
post-tetraploid HPT1) and three patients with trisomy syndromes are shown, in order to 
identify commonly upregulated (red) or downregulated (green) markers. 
 
Figure 3. Representative gating strategy for immunophenotypic analysis of mouse tumors.  
Cells were first gated in a FSC-A vs SSC-A plot (A), followed by dead cell and doublet 
exclusion on a PE-A vs PI-A (B) and FSC-A vs FSC-H plot (C), respectively. The tumor samples 
and control tissue (normal mammary gland) included in each screening were then 
individually gated based on VioBlue-A detection (VioDye+ cells) and non-tumor cell (NTC; 
FITC+ or APC+ cells) exclusion; R16 tumor sample (dark blue gate; NTC, light blue gate) and a 
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control (black gate) are represented (D). The level of CD73 expression for the three 
populations (E) and the percentage of CD73+ tumor cells (F) are shown. (G-I) Histograms 
indicate the level of CD73 expression in all tumor samples analyzed (R1, R4 and R15, red 
lines; R5, R10 and R3, green lines) compared to normal mammary gland (CTRL, black lines).  
 
Figure 4. CD73 expression is increased in aneuploid cells growing under high confluency  
(A) The graphs show the percentage of CD73+ cells in HCT116 and two trisomy 21 clones 
growing under normal conditions (dotted line) or under high confluency (solid line) for 18 
days. Data are reported as mean and standard deviations for three replicates from two 
independent experiments. Statistical analysis was performed using the two-way ANOVA to 
compare differences between groups per each time point. (*) represents time points which 
showed statistically a significant difference compared to the previous time point (p<0.0001). 
(B) Representative dotplots of FSC-A vs %CD73+ cells for control and confluent cells at day 18 
are shown, for HCT116 parental cells (top plots), HCT116 21/3 cl1 (center plots) and HCT116 
21/3 cl3 (bottom plots).  
 
Figure 5. Oxidative and ER stress in aneuploid cells and its effect on CD73, CD230, CD49b 
and CD95 expression and cell death.  
Higher levels of aneuploidy correlate with higher expression of protein disulfide isomerase 
(PDI), an ER stress marker (A), as well as higher reactive oxygen species (ROS), as shown by 
the CellROX fluorescent ROS indicator. Aneuploid clones show higher generation of ROS 
after treated with 100µM H2O2 18h (grey bars) compared to parental cells (B). Serum-
starvation (0% FBS; grey bars) for 3 days, rather than glucose-deprivation (white bars), 
increased the generation of ROS (C), with correlating increased expression of CD230, CD73, 
CD49b and CD95 in at least one of the cell lines (D). Effect of 3 day-serum starvation after 
CD230 siRNA knockdown on cell death, analyzed by percentage of apoptotic (AnnexinV+) and 
necrotic (DAPI+) cells on HCT116 parental and HPT1 post-tetraploid cell lines (E). Data are 
reported as mean and standard deviations for three replicates from two independent 
experiments and statistical analysis was performed using the two-way ANOVA (*p<0.01 and 
**p<0.0001).  
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